



DO NOT  
enter  
S. G.  
12/12/05

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No.05-860-US)  
(Formerly Case. No. 13761-7065)

In re Application of: )  
Laurie DeLeve )  
Serial No.: 10/086,072 ) Group Art Unit: 1617  
International Filing Date: February 27, 2002 ) Examiner: Sharareh  
For: Compositions and methods for preventing ) Confirmation No.: 1401  
and treating sinusoidal obstruction syndrome)  
and radiation-induced liver disease )

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO THE OFFICE ACTION MAILED AUGUST 26, 2005**

Sir:

Responsive to the Office Action mailed August 26, 2005, Applicants respectfully request reconsideration of the pending claims in view of the following amendments and remarks.

*DO NOT  
ENTER*

*SJM*

*In the claims*

1. (Previously presented) A method for prophylaxis or treating Sinusoidal Obstruction Syndrome in a human patient in need thereof, comprising administering an effective amount of a matrix metalloprotease inhibitor that inhibits up-regulation of MMP-9 and/or MMP-2 isoenzymes, wherein the matrix metalloprotease inhibitor is selected from the group consisting of 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid, Marimastat, Prinomastat, RS-130,830, (N-hydroxy-2(R)-[4-methoxysulfonyl]3-picollyl)amino]-3-methylbuteamide hydrochloride) monohydrate, Solimastat, BAY 12-9566, (3(R)(cyclopentylmethyl)-2(R)-[3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-4-oxo-4-piperidinobutyrohydroxamic acid), BMS-272591, Ilomastat, D2163, Metastat, Neovastat, and Periostat.
2. (Previously presented) A method for prophylaxis or treating chemotherapy-or radiation-induced liver disease in a human patient in need thereof, comprising administering an effective amount of a matrix metalloprotease inhibitor that inhibits up-regulation of MMP-9 and/or MMP-2 isoenzymes, wherein the matrix metalloprotease inhibitor is selected from the group consisting of 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid, Marimastat, Prinomastat, RS-130,830, (N-hydroxy-2(R)-[4-methoxysulfonyl]3-picollyl)amino]-3-methylbuteamide hydrochloride) monohydrate, Solimastat, BAY 12-9566, (3(R)(cyclopentylmethyl)-2(R)-[3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-4-oxo-4-piperidinobutyrohydroxamic acid), BMS-272591, Ilomastat, D2163, Metastat, Neovastat, and Periostat.
3. (Previously presented) The method of claim 2, wherein said chemotherapy-induced liver disease includes Sinusoidal Obstruction Syndrome, nodular regenerative hyperplasia peliosis hepatic, immunosuppression-induced hepatic venoocclusive disease, and sinusoidal dilatation.

4-20. (Canceled)